Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast ...

A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with oestrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of ...

“Our data shows that as many as 20% of breast cancer survivors on aromatase inhibitors will stop taking their medication ...

Dawn L. Hershman, MD, MS, will present work at SABCS 2023 that uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors ...

How long is long enough ― or too long ― when it comes to adjuvant aromatase inhibitor (AI) therapy for postmenopausal women with early-stage hormone receptor–positive (HR+) breast cancer? That's a ...

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. More common side effects of Kisqali may include diarrhea, nausea, infection, fatigue, and ...

The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel ...

CHICAGO (Reuters) - U.S. researchers may have found a way to overcome resistance to hormone-blocking breast cancer drugs, extending the life of treatments that keep the disease in check. They said the ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.